康方重磅新药完成首例受试者入组！T+0交易的恒生生物科技ETF(513280)收涨3.5%！政策重磅利好，商保目录落地打开支付空间

Group 1 - The core viewpoint of the news highlights a significant rise in the innovative drug sector, with the Hang Seng Biotechnology ETF (513280) increasing by 3.5% and showing net inflows for 3 out of the last 5 days, making it the only ETF in its index with positive growth in shares this year [1][3] - The A-share innovative drug sector also saw gains, with the Biopharmaceutical ETF (159839) rising by 1.72% [1] - Notable stock performances include Kangfang Biotech rising over 14%, and other companies like Innovent Biologics and CSPC Pharmaceutical Group also showing significant increases [3] Group 2 - Kangfang Biotech announced the completion of the first patient enrollment in the Phase Ia clinical study for its dual-target ADC drug AK146D1, which targets Trop2 and Nectin4 for treating advanced solid tumors [3][4] - AK146D1 is the first dual-target ADC drug to enter clinical stages for Kangfang Biotech, having received approvals from the FDA, TGA, and the National Medical Products Administration for clinical trials [4] - The drug aims to enhance efficacy and reduce resistance and toxicity by targeting both Trop2 and Nectin4, which are promising tumor targets [4] Group 3 - New policies have been introduced to support the development of innovative drugs, including measures from the National Healthcare Security Administration and the National Health Commission aimed at enhancing the quality of innovative drug development [4][5] - The introduction of a commercial health insurance directory for innovative drugs is expected to expand market opportunities and incentivize pharmaceutical companies to increase R&D efforts [5][6] - The measures include optimizing drug directory access policies and promoting the global market development of innovative drugs [5] Group 4 - The Hang Seng Biotechnology ETF (513280) is noted for its high proportion of innovative drugs and is the only ETF in its category to have net inflows this year, with a year-to-date share change of 11.40% [7] - The ETF is also recognized for having the lowest management fees among Hong Kong pharmaceutical ETFs, making it an attractive option for investors [7] - The Biopharmaceutical ETF (159839) focuses on leading companies in the sector, emphasizing a higher concentration and potential for growth [7]